Equities

Zenith Capital Corp

ZENI.P:CVE

Zenith Capital Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.105
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Apr 30 2024202420232022
ASSETS
Cash And Short Term Investments0.160.030.01
Total Receivables, Net5.401.160.16
Total Inventory------
Prepaid expenses0.060.020.52
Other current assets, total0.010.170.32
Total current assets5.631.381.00
Property, plant & equipment, net0.020.100.22
Goodwill, net------
Intangibles, net1.021.000.88
Long term investments------
Note receivable - long term------
Other long term assets0.700.700.76
Total assets7.413.172.88
LIABILITIES
Accounts payable0.742.071.65
Accrued expenses4.900.01--
Notes payable/short-term debt5.274.433.48
Current portion long-term debt/capital leases0.50----
Other current liabilities, total0.350.170.24
Total current liabilities126.685.36
Total long term debt4.4600
Total debt104.433.48
Deferred income tax------
Minority interest------
Other liabilities, total111111
Total liabilities281817
SHAREHOLDERS EQUITY
Common stock929081
Additional paid-in capital13129.65
Retained earnings (accumulated deficit)(125)(116)(104)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.030.01--
Total equity(20)(15)(14)
Total liabilities & shareholders' equity7.413.172.88
Total common shares outstanding152148137
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.